{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:57Z","timestamp":1786998417188,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ymthe.2025.06.027","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T11:04:16Z","timestamp":1749899056000},"page":"4156-4174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models"],"prefix":"10.1016","volume":"33","author":[{"given":"Mar\u00eda Jos\u00e9","family":"Limeres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Gambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Fraude-El Ghazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Pretsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German A.","family":"Islan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio Rivero","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying K.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3144-8794","authenticated-orcid":false,"given":"Maximiliano L.","family":"Cacicedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.06.027_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3350\/cmh.2021.0093","article-title":"Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib2","series-title":"Hepatitis B","year":"2021"},{"key":"10.1016\/j.ymthe.2025.06.027_bib3","series-title":"Global Viral Hepatitis: Millions of People Are Affected","year":"2021"},{"key":"10.1016\/j.ymthe.2025.06.027_bib4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.06.027_bib5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/vaccines9090969","article-title":"A therapeutic hepatitis b virus dna vaccine induces specific immune responses in mice and non-human primates","volume":"9","author":"Pooter","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2025.06.027_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jgh.13459","article-title":"Chronic hepatitis B in children: Therapeutic challenges and perspectives","volume":"32","author":"Defresne","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044900","article-title":"HBsAg Inhibits IFN-\u03b1 Production in Plasmacytoid Dendritic Cells through TNF-\u03b1 and IL-10 Induction in Monocytes","volume":"7","author":"Shi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.06.027_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/jvh.12216","article-title":"Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen","volume":"21","author":"Jiang","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ymthe.2025.06.027_bib9","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.06.027_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5009\/gnl17233","article-title":"Immunotherapy for chronic hepatitis B virus infection","volume":"12","author":"Bertoletti","year":"2018","journal-title":"Gut Liver"},{"key":"10.1016\/j.ymthe.2025.06.027_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib13","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.ymthe.2025.06.027_bib14","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine","volume":"25","author":"Vandepapeli\u00e8re","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2025.06.027_bib15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/hep.20408","article-title":"Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers","volume":"40","author":"Mancini-Bourgine","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.06.027_bib16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","article-title":"Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues","volume":"22","author":"Godon","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.027_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings","volume":"59","author":"Xu","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.06.027_bib20","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.06.027_bib21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib22","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/sj.gt.3301997","article-title":"Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES","volume":"10","author":"Kim","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.06.027_bib23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/eji.200323287","article-title":"Role of T cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus","volume":"33","author":"Langlade-Demoyen","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.imlet.2006.05.004","article-title":"Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal\/lysosomal compartments","volume":"106","author":"Kang","year":"2006","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ymthe.2025.06.027_bib25","article-title":"Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.06.027_bib26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/biomedicines11030796","article-title":"Immortalized B Cells Transfected with mRNA of Antigen Fused to MITD (IBMAM): An Effective Tool for Antigen-Specific T-Cell Expansion and TCR Validation","volume":"11","author":"Wang","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2025.06.027_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4049\/jimmunol.180.1.309","article-title":"Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals 1","volume":"180","author":"Kreiter","year":"2008","journal-title":"J Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2567.2004.01823.x","article-title":"DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response","volume":"112","author":"De Arruda","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2025.06.027_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.06.027_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38751-8","article-title":"An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants","volume":"14","author":"Tai","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.06.027_bib32","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.06.027_bib33","series-title":"Global Hepatitis Report 2024 Action for Access in Low- and Middle-Income Countries","year":"2024"},{"key":"10.1016\/j.ymthe.2025.06.027_bib34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40249-024-01225-0","article-title":"Disparities in hepatitis B virus healthcare service access among marginalised poor populations: a mixed-method systematic review","volume":"13","author":"Li","year":"2024","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.ymthe.2025.06.027_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264062","article-title":"Hepatitis vaccination adherence and completion rates and factors associated with low compliance: A claims-based analysis of U. S. adults","volume":"17","author":"LaMori","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.06.027_bib36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/pathogens13070554","article-title":"Overview of Hepatitis B Vaccine Non-Response and Associated B Cell Amnesia: A Scoping Review","volume":"13","author":"Bello","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.ymthe.2025.06.027_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766534","article-title":"In Vivo Mouse Models for Hepatitis B Virus Infection and Their Application","volume":"12","author":"Du","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cmi.2013.43","article-title":"A mouse model for HBV immunotolerance and immunotherapy","volume":"11","author":"Yang","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib39","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.06.027_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/vaccines9010061","article-title":"Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans","volume":"9","author":"Cagigi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2025.06.027_bib41","first-page":"121","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","volume":"22","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2025.06.027_bib42","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20011983","article-title":"Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes","volume":"195","author":"Yoneyama","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.06.027_bib43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1348-0421.2012.00496.x","article-title":"Hepatitis B virus surface antigen can activate human monocyte-derived dendritic cells by nuclear factor kappa B and p38 mitogen-activated protein kinase mediated signaling","volume":"56","author":"Jan","year":"2012","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01539","article-title":"Induction of Robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells","volume":"8","author":"Lindgren","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib45","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.06.027_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0163-z","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2025.06.027_bib47","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2022.12.013","article-title":"Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models","volume":"78","author":"Su","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2017.03.011","article-title":"Therapeutic vaccination for chronic hepatitis B","volume":"23","author":"Kosinska","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1232","article-title":"Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures","volume":"10","author":"Jansen","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib50","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/eji.201747208","article-title":"IgG subclass and vaccination stimulus determine changes in antigen specific antibody glycosylation in mice","volume":"47","author":"Kao","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib51","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.celrep.2015.11.027","article-title":"A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors","volume":"13","author":"Kao","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.06.027_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00029","article-title":"Adjuvant effect of Bacille Calmette-Gu\u00e9rin on hepatitis B vaccine immunogenicity in the preterm and term newborn","volume":"9","author":"Scheid","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.836274","article-title":"R848 Adjuvant Laden With Self-Assembled Nanoparticle-Based mRNA Vaccine Elicits Protective Immunity Against H5N1 in Mice","volume":"13","author":"Zhuang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12865-018-0245-0","article-title":"Down selecting adjuvanted vaccine formulations: A comparative method for harmonized evaluation","volume":"19","author":"Younis","year":"2018","journal-title":"BMC Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fcimb.2019.00031","article-title":"The Combination Vaccine Adjuvant System Alum\/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization","volume":"9","author":"Ebensen","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib56","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.06.027_bib57","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2025.06.027_bib58","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02482-20","article-title":"A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib59","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1126\/sciimmunol.aaw7083","article-title":"Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes","volume":"4","author":"Awasthi","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib60","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2025.06.027_bib61","doi-asserted-by":"crossref","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.06.027_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl5344","article-title":"BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype","volume":"6","author":"Guerrera","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.713351","article-title":"Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24highCD38high Regulatory B Cells and Lower Levels of IL-10 Expression Compared to Responders","volume":"12","author":"K\u00f6rber","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib64","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4254\/wjh.v7.i24.2503","article-title":"Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine","volume":"7","author":"Walayat","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-023-00684-0","article-title":"Analyzing immune responses to varied mRNA and protein vaccine sequences","volume":"8","author":"Park","year":"2023","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2025.06.027_bib66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/liv.12081","article-title":"Management of acute hepatitis B and reactivation of hepatitis B","volume":"33","author":"Jindal","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.ymthe.2025.06.027_bib67","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1080\/21645515.2019.1607132","article-title":"Is the function of the HBeAg really unknown?","volume":"15","author":"Milich","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2025.06.027_bib68","doi-asserted-by":"crossref","first-page":"e12914","DOI":"10.1111\/sji.12914","article-title":"Effects of intrauterine exposure to maternal-derived HBeAg on T cell immunity in cord blood","volume":"92","author":"Huang","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib69","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/rmv.1885","article-title":"The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics","volume":"26","author":"Kramvis","year":"2016","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib70","first-page":"52","article-title":"Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection","volume":"1","author":"B\u00f6cher","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib71","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200298","article-title":"Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection","volume":"217","author":"Fumagalli","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.06.027_bib72","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.4049\/jimmunol.1502061","article-title":"Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination","volume":"196","author":"Zhu","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.027_bib73","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-024-00813-3","article-title":"A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression","volume":"9","author":"Zhao","year":"2024","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2025.06.027_bib74","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200840","article-title":"Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers","volume":"217","author":"Hehle","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.06.027_bib75","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/vaccines8030456","article-title":"Cross-protection of hepatitis b vaccination among different genotypes","volume":"8","author":"Inoue","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2025.06.027_bib76","series-title":"RNA Vaccines","first-page":"167","article-title":"Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases","author":"Vadovics","year":"2024"},{"key":"10.1016\/j.ymthe.2025.06.027_bib77","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41541-023-00786-9","article-title":"A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax","volume":"8","author":"Kunkeaw","year":"2023","journal-title":"NPJ Vaccin."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:27:11Z","timestamp":1782505631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625004782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1525001625004782"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.027","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.02.12.636533","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}